London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Kaeren and Wilson!
Several labs have been awarded contracts (ref bidstats) to provide additional lab capacity to test and trace until Oct/Nov. They were awarded in August so hopefully another round of contracts being issued soon.
Thx Wilson will look tonight
Hkk I'd suspect marketing will be working to instruction, remember GM stated they had turned down multiple media opportunities.
Kaeren I was surprised there are only around 30 labs approved and two of them St. Helens and Knowsley trust and metropolitan police are for antigen only!! Source ukas. Here's the site if anybody wants to mess about or even better post a list of the labs.
https://www.ukas.com/find-an-organisation/
CT thats why I posted a few of the accredited labs but there are many more , they facilitate overflow with the increased PCR testing. They list separately general population testing from Fit to Fly.
By Winter end I can see NCYT moving from AIM to main market, based on fundamentals or possible T/O...UK corporate governance regime does not apply to AIM companies and it will be a much more stable environment to be in.
Over the last 6 months NCYT has released some cracking news (followed by a 2 week rise) along with bad (normally exploited by traders)......what we're seeing at NCYT is normal higher level business and everything they are up to has been announced already....it's the news ii's want to hear I'm interested in?......I would guess along the lines of life after covid plans, diversification and possible buyout opportunities.....these plancs have been toched on and still cannot be confirmed and therefore not announced.......yet ;-)
RBM, I suspect it's timing. Theyve already stated their 100m forecast several times so it's a waste of time repeating it like these other companies.
We know they've got other products to announce (IMUPLEX/2nd gen Antibody etc). Half year results on 27th could be the day. The 2nd DHSC contract was announced on the same day as the AGM last year so it could be the 29th.
Agree Chris, each company will have their own specific story to tell. NCYT have a strong one, why don’t they simply tell it, rather than just sit on their hands?
Bonuses and pay offs to exiting directors, and a cheap share buy back? Great for BoD and Co, not so, for PI's but perfectly legal... and lets face it, most Aim Co's are far worse... again imo :(
IMO, it's almost Mickey mouse RNS....almost designed for the traders....I would want to know more about diversification of investment and how they plan to spend their profit....expansion plans etc.
This is not simply a matter of communication.
Sourcebio released an almost identical RNS to the MHC one and is down 20%.
The facts of the matter are that NCYT has a diverse covid testing portfolio which means it is best placed to handle changes in government/travel approach to testing.
Additionally, if you look at some of the testing labs (e.g Alpha Bio) that have been contracted by the government to provide additional lab support, you will see that they're already at max capacity and therefore could not support travel testing anymore. The governments move to LFTs for travel is to increase PCR capacity going into winter. Again, NCYT are positioned to capitalise on that.
It ain’t rocket science, is it?
Mon, 20th Sep 2021 07:00
RNS Number : 2278M
MyHealthChecked PLC
20 September 2021
The ' Statement re. COVID-19 testing' announcement for MyHealthChecked plc released on 17 September 2021 at 17:50 under RNS No 2130M has been re-released in the interests of market clarity.
The announcement text is unchanged and is reproduced in full below.
MyHealthChecked plc
("MyHealthChecked" or "the Company")
Statement re. COVID-19 testing
MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, notes the recent Government statement regarding measures to simplify international travel.
As announced in the 7 July Trading update H1 revenues dramatically increased to £3.27m (H1 2020: £12,700) driven by COVID-19 testing services. This trend has continued into Q3 with monthly testing volumes exceeding those seen in the final two months of H1. Further information on Q3 trading will be provided in the results statement scheduled for Wednesday 29 September 2021.
Whilst the Government has announced the removal of Day 2 testing from an October date to be confirmed, the Directors remain confident that monthly testing volumes will remain a significant contributor to growth throughout the remainder of the financial year, even with levels naturally lower than the peak levels seen around summer holiday period. These revenues are still expected to contribute significantly to the results for the financial year ending 31 December 2021 and the Directors remain very optimistic about the business prospects for the full year.
The requirements surrounding PCR testing for out-bound travel, the "Fit to Fly" scheme, have not changed and Directors expect to see these volumes continuing. The Directors also expect that these newly announced changes to international travel will encourage more people to travel abroad from the UK, and that this will contribute to a rise in out-bound testing volumes.
As already stated, the Company's genomic testing service has been focussed on its COVID-19 testing offering, however it provides the foundation to create a wider portfolio of easy to use DNA tests over the longer-term. MyHealthChecked plc has a strong pipeline of genetic tests outside of COVID-19 to ensure long-term sustainable revenue growth.
For further information contact: